TY - JOUR
T1 - Low-dose and very low-dose spironolactone in combination therapy for essential hypertension
T2 - Evaluation by self-measurement of blood pressure at home
AU - Hanazawa, Tomohiro
AU - Obara, Taku
AU - Ogasawara, Kei
AU - Shinki, Takahiro
AU - Katada, Sakiko
AU - Inoue, Ryusuke
AU - Metoki, Hirohito
AU - Asayama, Kei
AU - Kikuya, Masahiro
AU - Ohkubo, Takayoshi
AU - Mano, Nariyasu
AU - Imai, Yutaka
N1 - Funding Information:
This work was supported by Grants for Scientific Research (1854042 and 207477) from the Ministry of Education, Culture, Sports, Science, and Technology, and grants from the National Cardiovascular Center in Japan.
PY - 2011/11
Y1 - 2011/11
N2 - Low-dose (25 mg) or very low-dose (12.5 mg) spironolactone were added among 86 uncontrolled hypertensive patients who were undergoing monotherapy with calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin AT1-receptor blockers (ARBs). Morning home systolic/diastolic blood pressure (BP) reduction was similar among the CCB (n = 30, -8.2/-2.6 mmHg), ACEI (n = 22, -13.0/-4.7 mmHg), and ARB (n = 34, -11.5/-5.1 mmHg) groups. An increase in serum potassium correlated positively with the decline in morning systolic BP. Even very low-dose (12.5 mg) spironolactone is clinically effective, although serum potassium should be carefully monitored.
AB - Low-dose (25 mg) or very low-dose (12.5 mg) spironolactone were added among 86 uncontrolled hypertensive patients who were undergoing monotherapy with calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin AT1-receptor blockers (ARBs). Morning home systolic/diastolic blood pressure (BP) reduction was similar among the CCB (n = 30, -8.2/-2.6 mmHg), ACEI (n = 22, -13.0/-4.7 mmHg), and ARB (n = 34, -11.5/-5.1 mmHg) groups. An increase in serum potassium correlated positively with the decline in morning systolic BP. Even very low-dose (12.5 mg) spironolactone is clinically effective, although serum potassium should be carefully monitored.
KW - Anti-hypertensive drugs
KW - Combination therapy
KW - Home blood pressure
KW - Hypertension
KW - Spironolactone
UR - http://www.scopus.com/inward/record.url?scp=80053644796&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053644796&partnerID=8YFLogxK
U2 - 10.3109/10641963.2010.531844
DO - 10.3109/10641963.2010.531844
M3 - Article
C2 - 21777149
AN - SCOPUS:80053644796
SN - 1064-1963
VL - 33
SP - 427
EP - 436
JO - Clinical and Experimental Hypertension
JF - Clinical and Experimental Hypertension
IS - 7
ER -